Efficacy and Safety of Timolol for TKI Induced Paronychia
Status:
Recruiting
Trial end date:
2024-03-31
Target enrollment:
Participant gender:
Summary
This study would assess the clinical efficacy of add-on topical timolol 0.5% gel to
betamethasone valerate 0.1% for the treatment of EGFR-TKI induced paronychia. Eligible
patients, who develop paronychia (affecting fingernails, toenails or both), will be included
in this study. They will be randomized in 1:1 ratio using computer-generated randomization
list to receive either combination of topical timolol 0.5% gel and betamethasone valerate
0.1% lotion application twice daily or betamethasone valerate 0.1% lotion application twice
daily. Patients in timolol combination treatment group will receive topical timolol 0.5% gel
twice daily with occlusion (i.e. covered with adhesive badge) and betamethasone valerate 0.1%
lotion twice daily with occlsuion for 1 month. Patients in routine arm would receive the
management according to routine clinical practice, including prescription of betamethasone
valerate 0.1% lotion twice daily for 1 month with occlusion. For patients who do not have
paronychia completely resolved after 4 weeks, the treatment assigned will be continued for
another 4 to 8 weeks , up to 12 weeks to see the effect.